Discuss adjusting your T1D management with your doctor
This is due to the longer duration of effect of the long-acting medication compared to short-acting agonists
[100] In addition to the above controversies presented in PubMed by different research groups, a fundamental question that remains to be addressed is: although GLP-1 or GLP-1RAs may get access to the brain via a rapid and passive receptor-independent mechanism, [88,89] or by a receptor-mediated event, [95] does such access physiologically and pharmacologically relevant to their brain functions
Instead, explain simply that research is underway, but we dont have enough proof yet that this treatment works for that condition. Moreover, relate the discussion to the patients goals
In the pancreas, GLP-1 binding to its receptors stimulates the secretion of insulin, which helps to lower blood sugar levels